Table 1.
Demographic information for patients and healthy control participants.
| HC | Patients (Whole sample) | Patients (EDSS ≤ 1) | Patients (EDSS ≥ 2) | pa | |
|---|---|---|---|---|---|
| N | 101 | 101 | 36 | 39 | |
| Sex (F/M) | 67/34 | 67/34 | 20/16 | 27/12 | |
| Age (Mean ± SD years) | 35.04 ± 10.33 | 36.11 ± 10.33 | 31.55 ± 6.12 | 40.21 ± 11.64 | < 0.001* |
| EDSS (Median (IQR)) | NA | 1.5 (1.5) | 1 (1) | 2.5 (1) | < 0.001* |
| Disease duration (Mean ± SD years) | NA | 7.07 ± 7.99 | 4.24 ± 3.46 | 10.86 ± 10.49 | < 0.001* |
|
MS-specific Medication (n) If yes, which? (n) |
NA | Yes (70) | Yes (23) | Yes (31) | |
| No (27) | No (13) | No (8) | |||
| Not reported (4) | |||||
| Interferon beta (10) | Interferon beta (4) | Interferon beta (4) | |||
| Glatiramer acetate (20) | Glatiramer acetate (9) | Glatiramer acetate (8) | |||
| Fumarate (15) | Fumarate (6) | Fumarate (4) | |||
| Azathioprine (1) | Natalizumab (1) | Azathioprine (1) | |||
| Natalizumab (4) | Fingolimod (2) | Natalizumab (2) | |||
| Fingolimod (11) | Other (1) | Fingolimod (6) | |||
| Teriflunomide (3) | Teriflunomide (3) | ||||
| Other (6) | Other (3) |
HC: healthy control participants; MS EDSS ≤ 1: MS patients with Expanded disability status scale score<1; MS EDSS ≥ 2: MS patients with Expanded disability status scale score greater than 2; SD: standard deviation; EDSS: Expanded disability status scale; IQR: interquartile range; NA: not applicable.
a
p-value corresponding to permutation-based null estimation of T-statistic between MS patients with EDSS≤1 and MS patients with EDSS≥2.